头顶“国”字头的中国中药,却在税务稽查与自查过程中补税过亿元,不仅严重侵蚀了企业利润,更暴露出合规管理方面的深层漏洞。3月25日晚,中国中药发布2024年度的业绩报告显示,2024年该公司营收165.1亿元,同比下降8.9%;净利润仅2077万元,同比锐减98.5%,创下近五年来最大跌幅。这份近乎“归零”的成绩单,不仅折射出中药企业在集采常态化与市场需求结构性变化下的挑战,更将中国中药自身的战略...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.